Biotech and Pharmaceuticals Medicine

More

  • Quarterly net profit fell to $3.5 billion from $4.5 billion a year earlier. Adjusting for one-time items, Gilead earned $3.08 per share, which beat analysts' average estimate of $3.02, according to Thomson Reuters I/B/E/S. The company on Monday lowered its outlook for 2016 product sales to between $29.5 billion and $30.5 billion, from a previous range of $30...

  • LARAMIE, Wyo.— Work is underway at the Wyoming State Veterinary Laboratory to add a biohazard facility that will focus on the nasty diseases found in some Wyoming wildlife, like the plague and rabies. Director William Laegreid said the upgraded "biosafety level 3" laboratory will allow veterinarians to keep the main facility open when an animal shows up with a...

  • US Hospitals struggle to earn 5-star rating

    Federal health regulators say only about 2-percent of the nation's hospitals received the highest-quality rating.

  • Valeant Pharmaceuticals said U.S. regulators have raised concerns over a new eye drop manufactured at a Bausch + Lomb facility in Florida.

  • July 22- Valeant Pharmaceuticals International said on Friday U.S. regulators have raised concerns over a new eye drop manufactured at a Bausch+ Lomb facility in Florida. The U.S. Food and Drug Administration, in a complete response letter regarding the eye drop for a type of glaucoma, raised concerns over Current Good Manufacturing Practice at the unit.

  • LONDON, July 22- Scientists are opening a new front in the war on cancer with plans to develop "anti-evolution" drugs to stop tumour cells from developing resistance to treatment. Britain's Institute of Cancer Research, one of the world's top cancer centres, said on Friday its initiative was the first to have at its heart the target of overcoming cancer evolution...

  • Regeneron Pharmaceuticals

    Big drug discoveries have been scant, but investors can find long-term value in some biotech names, said Mark Schoenebaum of Evercore ISI.

  • July 21- Biogen Inc's quarterly adjusted profit blew past Wall Street estimates on higher sales of its multiple sclerosis drugs, and the company said Chief Executive George Scangos would leave in the coming months. Biogen's hemophilia drugs, Eloctate and Alprolix, posted sales of $125 million and $80 million, respectively, above estimates of $190 million.

  • WASHINGTON— The brain's nerve cells communicate by firing messages to each other through junctions called synapses, and problems with those connections are linked to disorders like Alzheimer's and epilepsy. Now Yale University researchers have developed a way to picture synapses in living brains. To find a non-invasive approach, the Yale- led team...

  • July 19- Zafgen Inc said it was suspending the development of its lead obesity drug, beloranib, more than six months after the U.S. Food and Drug Administration asked the company to halt all tests on the drug following the death of two patients. The FDA has approved drugs made by Vivus Inc, Orexigen Therapeutics Inc and Arena Pharmaceuticals Inc in the past few years,...

  • It said instrument and accessory revenue rose 14 percent as procedures using da Vincis climbed 16 percent, driven by growth in U.S. general surgeries, such as hernia repairs, and by growth in urological procedures, such as prostate surgeries, outside the United States. Procedures rose 25 percent outside the United States, helped by growth in Japan, China and South...

  • July 19- Zafgen Inc said it was suspending the development of its lead obesity drug, beloranib, more than six months after the U.S. Food and Drug Administration asked the company to halt all tests on the drug following the death of two patients. The U.S. Food and Drug Administration asked Zafgen to halt all tests on the drug in December after a second patient died from...

  • July 19- Zafgen Inc said it was suspending the development of its obesity drug, beloranib, and reducing its workforce by about 34 percent, sending its shares tumbling 41.9 percent in extended trading on Tuesday. In December, the U.S. Food and Drug Administration asked Zafgen to halt all tests on the drug after a second patient died from an artery blockage in the lung.

  • Martine Rothblatt.

    United Therapeutics' Martine Rothblatt says investors with vision should get into her biotech firm now, before it grows to Google-like proportions.

  • Retired wrestlers sue WWE

    More than 50 plaintiffs want compensatory and punitive damages as well as better medical monitoring.

  • July 19- Privately held Jounce Therapeutics Inc, which is working on treatments designed to use a patients' own immune systems to better attack cancer, said on Tuesday it had entered into an collaboration and investment agreement with Celgene Corp worth more than $2.5 billion. The deal for the tiny Cambridge, Massachusetts- based company comes just at little...

  • CHICAGO— Fracking may worsen asthma in children and adults who live near sites where the oil and gas drilling method is used, according to an 8- year study in Pennsylvania. Fracking and improved drilling methods led to a boom in production of oil and gas in several U.S. states, including Pennsylvania, North Dakota, Oklahoma, Texas and Colorado.

  • The New Jersey- based company's shares were up 7 percent at $3.21 in premarket trading on Monday. ALS, or Lou Gehrig's disease, is an invariably fatal neurological disorder that affects the nerve cells responsible for controlling voluntary muscles. About 6,000 people in the United States are diagnosed with ALS every year and as many as 20,000 Americans have the...

  • July 18- Drug developer Brainstorm Cell Therapeutics Inc said its experimental cell therapy was found safe and well tolerated in patients with amyotrophic lateral sclerosis, a progressive neurological disorder, in a mid-stage study. The New Jersey- based company's shares jumped 16 percent to $3.47 in premarket trading on Monday. ALS is an invariably fatal...

  • BRIEF-ARIA STUDY SHOWS SUPERIOR EFFICACY OF TRIUMEQ FOR. TREATMENT-NAïVE WOMEN WITH HIV@ with HIV@. *ARIA study shows superior efficacy of Triumeq for treatment-naïve women living with HIV.